Literature DB >> 12467748

The spectrum of pathology in central core disease.

C A Sewry1, C Müller, M Davis, J S M Dwyer, J Dove, G Evans, R Schröder, D Fürst, T Helliwell, N Laing, R C M Quinlivan.   

Abstract

Central core disease is a congenital myopathy with muscle weakness defined pathologically by the presence of extensive areas in muscle fibres that are devoid of oxidative enzyme activity. The gene responsible has been shown to be the ryanodine receptor 1 on chromosome 19q13 and mutations have now been identified in several patients. Some cases with the morphological defect remain molecularly undefined, particularly those studied before molecular studies were available. We have studied three families with congenital onset, each with a dominantly inherited mutation in a C-terminal exon of the ryanodine receptor 1. They illustrate the spectrum of pathology that can be observed in patients with the myopathic features of central core disease. We show that extensive fibrosis and fat may be present, type 1 fibre uniformity may occur in the absence of cores; cores may be central or peripheral, single or multiple; and that an appearance of multiple focal minicores might cause a diagnostic pathological dilemma. In addition, we show the value of immunocytochemistry in identifying cores, in particular the use of antibodies to desmin and gamma-filamin.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12467748     DOI: 10.1016/s0960-8966(02)00135-9

Source DB:  PubMed          Journal:  Neuromuscul Disord        ISSN: 0960-8966            Impact factor:   4.296


  39 in total

1.  Clinical utility gene card for: Central core disease.

Authors:  Suzanne Lillis; Stephen Abbs; Clemens R Mueller; Francesco Muntoni; Heinz Jungbluth
Journal:  Eur J Hum Genet       Date:  2011-10-12       Impact factor: 4.246

2.  Functional properties of ryanodine receptors carrying three amino acid substitutions identified in patients affected by multi-minicore disease and central core disease, expressed in immortalized lymphocytes.

Authors:  Sylvie Ducreux; Francesco Zorzato; Ana Ferreiro; Heinz Jungbluth; Francesco Muntoni; Nicole Monnier; Clemens R Müller; Susan Treves
Journal:  Biochem J       Date:  2006-04-15       Impact factor: 3.857

3.  Bayesian modeling to predict malignant hyperthermia susceptibility and pathogenicity of RYR1, CACNA1S and STAC3 variants.

Authors:  Senthilkumar Sadhasivam; Barbara W Brandom; Richard A Henker; John J McAuliffe
Journal:  Pharmacogenomics       Date:  2019-09       Impact factor: 2.533

4.  Loss of FilaminC (FLNc) results in severe defects in myogenesis and myotube structure.

Authors:  I Dalkilic; J Schienda; T G Thompson; L M Kunkel
Journal:  Mol Cell Biol       Date:  2006-09       Impact factor: 4.272

5.  Mild Clinical Features and Histopathologically Atypical Cores in Two Korean Families with Central Core Disease Harboring RYR1 Mutations at the C-Terminal Region.

Authors:  Na-Yeon Jung; Yeong-Eun Park; Jin-Hong Shin; Chang Hun Lee; Dae-Soo Jung; Dae-Seong Kim
Journal:  J Clin Neurol       Date:  2014-11-11       Impact factor: 3.077

Review 6.  Congenital myopathies.

Authors:  Claudio Bruno; Carlo Minetti
Journal:  Curr Neurol Neurosci Rep       Date:  2004-01       Impact factor: 5.081

7.  Ca2+ dysregulation in Ryr1(I4895T/wt) mice causes congenital myopathy with progressive formation of minicores, cores, and nemaline rods.

Authors:  Elena Zvaritch; Natasha Kraeva; Eric Bombardier; Robert A McCloy; Frederic Depreux; Douglas Holmyard; Alexander Kraev; Christine E Seidman; J G Seidman; A Russell Tupling; David H MacLennan
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-03       Impact factor: 11.205

8.  Characterization and temporal development of cores in a mouse model of malignant hyperthermia.

Authors:  Simona Boncompagni; Ann E Rossi; Massimo Micaroni; Susan L Hamilton; Robert T Dirksen; Clara Franzini-Armstrong; Feliciano Protasi
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-04       Impact factor: 11.205

9.  Central core disease: clinical, pathological, and genetic features.

Authors:  R M Quinlivan; C R Muller; M Davis; N G Laing; G A Evans; J Dwyer; J Dove; A P Roberts; C A Sewry
Journal:  Arch Dis Child       Date:  2003-12       Impact factor: 3.791

10.  A double mutation of the ryanodine receptor type 1 gene in a malignant hyperthermia family with multiminicore myopathy.

Authors:  Seul-Ki Jeong; Dong-Chan Kim; Yong-Gon Cho; Il-Nam Sunwoo; Dal-Sik Kim
Journal:  J Clin Neurol       Date:  2008-09-30       Impact factor: 3.077

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.